Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Inventory (2016 - 2025)

UroGen Pharma (URGN) has disclosed Inventory for 8 consecutive years, with $16.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 78.43% year-over-year to $16.5 million, compared with a TTM value of $16.5 million through Dec 2025, up 78.43%, and an annual FY2025 reading of $16.5 million, up 78.43% over the prior year.
  • Inventory was $16.5 million for Q4 2025 at UroGen Pharma, up from $8.3 million in the prior quarter.
  • Across five years, Inventory topped out at $16.5 million in Q4 2025 and bottomed at $3.3 million in Q1 2021.
  • Average Inventory over 5 years is $6.3 million, with a median of $5.3 million recorded in 2022.
  • The sharpest move saw Inventory soared 204.09% in 2021, then fell 10.49% in 2022.
  • Year by year, Inventory stood at $4.8 million in 2021, then fell by 10.49% to $4.3 million in 2022, then surged by 31.17% to $5.7 million in 2023, then surged by 62.65% to $9.2 million in 2024, then soared by 78.43% to $16.5 million in 2025.
  • Business Quant data shows Inventory for URGN at $16.5 million in Q4 2025, $8.3 million in Q3 2025, and $7.1 million in Q2 2025.